ESPRM 2018 | VILNIUS LITHUANIA
to view the content of this newsletter on your browser, please click here

 
 

Are you interested in rehabilitation and how to measure functioning in persons with genetic muscular dystrophies?

You may learn how to choose outcome measure, strategies to validate trials using new genetic therapies in persons
with genetic muscular dystrophies

Professor François Constant BOYER
and
Ghilas BOUSSAID with Algirdas UTKUS
and Andoni URTIZBEREA

invite you to Vilnius

Joint session AFM - ESPRM
(AFM-Téléthon - The French Muscular Dystrophy Association
and European Society of Physical and Rehabilitation Medicine)

Rehabilitation of rare disease and muscular dystrophies:
outcome measures preparing genetic therapies

21st EUROPEAN CONGRESS of PRM, 01-06 MAY 2018

SESSION ON: “ Persons with Genetic Neuromuscular Disease
Thursday May 3, 2018; Room Zeta : 17.00 - 19.00

CHAIRPERSONS:
François Constant BOYER, Ghilas BOUSSAID, Algirdas UTKUS, Andoni URTIZBERA

SPEAKERS:

Laurent SERVAIS
Clinical trial and outcome measures in Neuromuscular Disorders

Pisco DOMINGOS
Outcome measures in Duchenne muscular dystrophy and implications for clinical trials

Enzo RICCI
Muscle MRI as an outcome measure in neuromuscular diseases

Carole VUILLEROT
MFM measure and NMD: metrological powers

Antoine DANY, François Constant BOYER
Qol-gNMD, a new patient reported outcome measures validated with a Rasch model theory

For more information visit www.esprm2018.com

Newsletter prepared by François Constant BOYER and Jolanta KUJAWA.

To unsubscribe from receiving this newsletter click here